BRIEF-Wave Life Sciences Announces Positive Results From Phase 1B/2A Select-Hd Trial
June 25 (Reuters) - WAVE Life Sciences Ltd:
* WAVE LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM PHASE 1B/2A SELECT-HD TRIAL WITH FIRST CLINICAL DEMONSTRATION OF ALLELE-SELECTIVE MUTANT HUNTINGTIN LOWERING IN HUNTINGTON’S DISEASE
* WAVE LIFE SCIENCES LTD: STATISTICALLY SIGNIFICANT INCREASES WERE OBSERVED IN WTHTT PROTEIN VERSUS PLACEBO
* WAVE LIFE SCIENCES LTD: GENERALLY SAFE AND WELL-TOLERATED PROFILE ACHIEVED IN 30 MG MULTIDOSE COHORT
* WAVE LIFE SCIENCES: SEES CURRENT CASH & CASH EQUIVALENTS SUFFICIENT TO FUND OPERATIONS INTO Q4 2025 Source text for Eikon: Further company coverage: